ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Yiqi Guben capsule alleviates asthmatic airway inflammation through the miR-34a-5p/Notch1 pathway associated with Treg/Th17 immune balance.
Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore the mechanisms by which YQGB regulates the balance between regulatory T cells (Tregs) and T helper 17 cells (Th17) and clarify its role in the inflammatory response associated with asthma.
methodsA total of 60 BALB/c mice were randomly divided into six experimental groups: the control group, the OVA-induced asthma model group (OVA group), the high-dose YQGB treatment group (YQGB(H) group), the medium-dose YQGB (YQGB(M) group), the low-dose YQGB (YQGB(L) group), and the dexamethasone positive control (DEX group). Serum and lung tissue samples were collected to evaluate inflammatory cytokine expression, Treg and Th17 cell proportions, an relevant molecular markers. In vitro, LPS-stimulated MH-S monocultures and MH-S/CD4
resultsOur results showed that YQGB decreased the expression of IL-6, IL-17 A, IL-23, GM-CSF, and Notch1 and promoted the expression of anti-inflammatory cytokines (IL-10 and IL-35) and miR-34a-5p in vivo and in vitro. In mice with OVA-induced asthma, YQGB restored the imbalance in Treg/Th17 and alleviated inflammation and EMT. In LPS-induced MH-S cells, YQGB attenuated inflammatory activation by inhibiting macrophage proliferation and enhancing apoptosis. Additionally, LPS stimulation considerably decreased miR-34a-5p expression, while increasing Notch1 expression.
conclusionYQGB alleviates asthmatic airway inflammation, accompanied by altered Treg/Th17 immune balance. Although its therapeutic effects correlate with the miR-34a-5p/Notch1 axis, the causal cascade linking this axis to Treg/Th17 homeostasis remains unproven, indicating its potential as a candidate asthma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.